Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension

Chest

Volumn 133, Issue 1, 2008, Pages 183-189

  Pepke Zaba, Joanna ^a   Gilbert, Claire ^b   Collings, Lorraine ^b   Brown, Martin C J ^b  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Patient perceived benefits; Pulmonary hypertension; Sildenafil; Sustained improved quality of life

Indexed keywords

PLACEBO; SILDENAFIL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EXERCISE; FEMALE; HEALTH STATUS; HUMAN; MALE; OPEN STUDY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; QUESTIONNAIRE; SHORT FORM 36; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 38349081419     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-0592     Document Type: Article

References (23)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351:1425-1436
2. Galiè N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: the Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25:2243-2278
3. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351:1655-1665
4. Flattery MP, Pinson JM, Savage L, et al. Living with pulmonary artery hypertension: patients' experiences. Heart Lung 2005; 34:99-107
5. Shafazand S, Goldstein MK, Doyle RL, et al. Health-related quality of life in patients with pulmonary arterial hypertension. Chest 2004; 126:1452-1459
6. Cenedese E, Speich R, Dorschner L, et al. Measurement of quality of life in pulmonary hypertension and its significance. Eur Respir J 2006; 28:808-815
7. Coons SJ, Rao S, Keininger DL, et al. A comparative review of generic quality-of-life instruments. Pharmacoeconomics 2000; 17:13-35
8. Kopec JA, Willison KD. A comparative review of four preference-weighted measures of health-related quality of life. J Clin Epidemiol 2003; 56:317-325
9. Higginson IJ, Carr AJ. Measuring quality of life: using quality of life measures in the clinical setting. BMJ 2001; 322:1297-1300
10. Ferguson RJ, Robinson AB, Splaine M. Use of the reliable change index to evaluate clinical significance in SF-36 outcomes. Qual Life Res 2002; 11:509-516
11. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334:296-302
12. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165:800-804
13. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322-329
14. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41:2119-2125
15. Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 170:1212-1217
16. McKenna SP, Doughty N, Meads DM, et al. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 2006; 15:103-115
17. Höper MM, Oudiz RJ, Peacock A, et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 2004; 43:S48-S55
18. Ware JE Jr, Snow KK, Kosinski M. SF-36 health survey: manual and interpretation guide. Lincoln, RI: Quality Metric Inc, 2000
19. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001; 33:337-343
20. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148-2157
21. Enright PL. The six-minute walk test. Respir Care 2003; 48:783-785
22. Okamoto LJ, Noonan M, DeBoisblanc BP, et al. Fluticasone propionate improves quality of life in patients with asthma requiring oral corticosteroids. Ann Allergy Asthma Immunol 1996; 76:455-461
23. Walters SJ. Sample size and power estimation for studies with health related quality of life outcomes: a comparison of four methods using the SF-36. Health Qual Life Outcomes 2004; 2:26